论文部分内容阅读
目的探讨急性ST段抬高型心肌梗死早期溶栓治疗的效果和安全性。方法对2014年1月至2016年1月期间在我院治疗的急性ST段抬高型心肌梗死进行回顾性分析,将患者随机分为溶栓组(试验组)30例和抗凝组(对照组)30例,溶栓组采用普佑克(重组人尿激酶原)溶栓治疗,抗凝组采用低分子肝素钠配合肠溶阿司匹林片、硫酸氢氯吡格雷片治疗。根据心肌梗死溶栓分级标准(TIMI)来判定血管再通率。结果溶栓治疗后,试验组患者的再通率(80.00%)优于对照组(50.00%),试验组患者的完全再通率(73.33%)优于对照组(40.00%),差异均具有统计学意义(P<0.05),试验组患者的梗死后心绞痛发病率(16.67%)优于对照组(46.67%),差异具有统计学意义(P<0.05)。结论采用重组人尿激酶原溶栓治疗急性心肌梗死患者具有疗效可靠和安全性高的显著优势,值得临床的广泛应用和推广。
Objective To investigate the efficacy and safety of early thrombolysis in patients with acute ST-segment elevation myocardial infarction. Methods A retrospective analysis of acute ST-segment elevation myocardial infarction treated in our hospital from January 2014 to January 2016 was performed. The patients were randomly divided into thrombolysis group (experimental group) 30 and anticoagulation group (control group Group). Thrombolytic group was treated with Prussian (recombinant human prourokinase) thrombolytic therapy. The anticoagulation group was treated with low molecular weight heparin with enteric-coated aspirin tablets and clopidogrel bisulfate tablets. According to myocardial infarction thrombolysis grading standards (TIMI) to determine the rate of vascular recanalization. Results After thrombolysis, the recanalization rate (80.00%) in the test group was superior to that in the control group (50.00%). The complete recanalization rate (73.33%) in the test group was superior to that in the control group (40.00%), The incidence of post-infarction angina (16.67%) in the experimental group was superior to that in the control group (46.67%) (P <0.05). The difference was statistically significant (P <0.05). Conclusion Recombinant human prouromaginase thrombolysis in the treatment of patients with acute myocardial infarction with reliable and safe and significant advantages, it is widely used in clinical and promotion.